IMVT · Immunovant

The thesis

Immunovant's rheumatoid arthritis result on 9 November 2026 revives the case for its drug IMVT-1402 (imeroprubart), and the shares are modestly more likely than not to beat the S&P 500 over three months. The evidence is narrower than the headline: only the 600 mg dose beat placebo, and two secondary measures missed. FDA feedback on a registrational path, guided for late 2026 or early 2027, and the 2027 Graves' disease and myasthenia gravis toplines settle whether the gain holds.

The shares closed at $35.05 on 12 November 2026. That compares with $28.39 on 5 November 2026 and $30.53 on 6 November 2026, the last close before the data. The 9 November 2026 close of $35.15 was a one-day rise of 15.13% (Motley Fool). The shares reached $37.04 on 11 November 2026 and closed 22.8% below the 52-week intraday high of $45.42 set on 19 August 2026. The three-month change is −16.2%.

The rise followed seven weeks of decline after the 23 September 2026 cutaneous lupus failure. On 9 November 2026 the company also filed a prospectus for a mixed securities offering with terms undisclosed, according to company news, so share issuance into strength is possible.

The rating is Medium because the first placebo-controlled win in a large indication is new evidence, while a possible offering and an unresolved FDA path keep the odds only modestly above even.

Bullish and bearish views on Immunovant, Inc.

The bull case on Immunovant, Inc. (IMVT), in brief: primary endpoint met at 600 mg. The bear case: only one dose worked.

Bull case

• Primary endpoint met at 600 mg. In the randomized withdrawal period, 92.5% of patients on 600 mg kept an ACR20 response at Week 28 against 75.6% on placebo (p=0.0139), per Korea Biomedical Review on 9 November 2026. ACR20 is the American College of Rheumatology's measure of 20% improvement in disease activity.
• Deeper responses also separated. The exploratory ACR50 rate was 80% on 600 mg against 56.1% on placebo (p=0.0117), reported 9 November 2026. The trial was not powered for ACR50, so the p-value is nominal.
• Patients had failed other drugs. The study enrolled patients with an inadequate response to at least two advanced therapies. In the subgroup that had failed both JAK and TNF inhibitors, ACR20 was 92%, consistent with the overall group (Korea Biomedical Review, 9 November 2026).
• Clean safety in Period 2. The company reported no serious adverse events, no Grade 3 or higher events and no discontinuations for adverse events in any arm (9 November 2026).
• Analysts raised targets after the data. Wells Fargo kept Overweight and raised its target to $47 on 10 November 2026. Truist kept Hold and raised its target to $33 the same day.
• Cash funds the plan. Cash was $722.3 million at 30 September 2026, and research and development expense fell to $85.0 million from $114.2 million a year earlier. Management says cash funds operations through a potential Graves' disease launch (Motley Fool transcript, 9 November 2026). Fiscal second-quarter EPS of −$0.47 beat the −$0.71 estimate (Benzinga, 9 November 2026).

Bear case

• Only one dose worked. The 300 mg arm reached a 75% response rate against 75.6% on placebo (p=0.9426), reported 9 November 2026. A registrational programme would rest on a single dose.
• Two secondary measures missed. The Clinical Disease Activity Index (p=0.1096) and the Simplified Disease Activity Index (p=0.1299) favoured 600 mg numerically but were not significant (Korea Biomedical Review, 9 November 2026).
• Small trial, high placebo response. The study randomized 117 patients in Period 2, and 75.6% of withdrawn patients on placebo still met ACR20 at Week 28. The sample is small for a registrational decision.
• Possible dilution. The 9 November 2026 prospectus leaves terms undisclosed (company news). Cash fell from $797.8 million at 30 June 2026 to $722.3 million at 30 September 2026.
• Pipeline has narrowed. Cutaneous lupus was dropped after the 23 September 2026 miss. On 9 November 2026 management said it will not pursue Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial. Argenx stopped its Phase 3 Sjögren's study for futility on 8 October 2026.
• Mixed sell-side view. Truist's target of $33, set 10 November 2026 with a Hold rating, sits below the 12 November 2026 close of $35.05.
• Insider selling continues. Director Atul Pande sold 3,000 shares at $36.00 on 11 November 2026 under a Rule 10b5-1 plan (SEC Form 4, filed 12 November 2026). Chief Financial Officer Tiago Girao sold 6,606 shares at $28.50 on 28 October 2026 (SEC Form 4).

Price setup

The shares closed at $35.05 on 12 November 2026, above the 50-day average of $32.74 and the 200-day average of $32.31. Both averages sit between the pre-data closes of $28.39 and $30.53 and the post-data closes of $35.15 to $37.04.

The 11 November 2026 close of $37.04 is the post-data high. The 52-week intraday high is $45.42 on 19 August 2026, and the 52-week closing low is $22.02 on 2 December 2025.

The one-day rise of 15.13% on 9 November 2026 and the pending offering prospectus are the main signs of crowding. SEC Form 4 filings show sales by officers and one director since 23 September 2026, and no purchases.

Catalysts ahead

• ~31 December 2026 (est.): FDA discussions on a registrational path in difficult-to-treat rheumatoid arthritis, guided for late 2026 or early 2027. Decides whether a single-dose 600 mg result can anchor a registrational programme.
• ~30 June 2027 (est.): Potentially registrational Graves' disease and myasthenia gravis toplines, guided for 2027. These readouts carry most of the asset's value after the lupus miss and the Sjögren's deprioritisation.

What would change the view

A daily close below $30, under the 6 November 2026 close of $30.53 that preceded the rheumatoid arthritis data, which would erase the post-data gain. FDA feedback requiring more than the 600 mg single-dose result, or Graves' or myasthenia gravis toplines slipping beyond 2027, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• The FDA asks for more than the 600 mg single-dose result, delaying or reshaping a registrational programme. Confirmed by: management reporting FDA feedback that requires a larger or differently designed trial, or no feedback by early 2027.
• Equity issuance after the 9 November 2026 rise dilutes holders and caps the gain. Confirmed by: a priced offering under the 9 November 2026 prospectus at a discount to the 12 November 2026 close of $35.05.
• The missed secondary measures and the 300 mg miss point to a weaker effect than the primary endpoint suggests. Confirmed by: a later controlled rheumatoid arthritis trial failing to repeat the 600 mg separation from placebo.
• Class-wide doubt about immunoglobulin G lowering in new diseases returns. Confirmed by: another controlled failure in the class, as with argenx's Sjögren's futility stop on 8 October 2026.

What it trades with

Argenx is the closest read-across: its 8 October 2026 Sjögren's futility finding moved Immunovant 4.8% lower in pre-market trading that day (Benzinga). Roivant Sciences is Immunovant's majority shareholder and issues its own releases on Immunovant news. HanAll Biopharma licensed the core IMVT-1402 technology and is also reported as a partner. The shares trade with the wider immunoglobulin G-lowering drug class and with small-cap biotech risk appetite.